{"schema_version":"secwatch.filing_event.v1","accession":"0001372299-25-000004","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.091215+00:00","generated_at":"2026-05-19T04:28:18.888770+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Ocugen presents clinical data with significant LLVA improvement (p=0.005) at Year 1 in retinal disease study","bullets":["Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).","75% of patients met responder criterion (6/8) at measured timepoints.","Mean total atrophy area change at Month 12 showed trend favoring treated eye (p=0.055).","Mean BCVA (ETDRS) change from baseline reported up to Month 12.","Presentation includes Year 1 and Year 2 data from the clinical trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001372299-25-000004","json":"https://secwatch.observer/filing/0001372299-25-000004.json","markdown":"https://secwatch.observer/filing/0001372299-25-000004.md","text":"https://secwatch.observer/filing/0001372299-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/0001372299-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/ocgn-20250616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:28:18.888770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}